It is estimated that 5% of babies are born with a genetic disorder. Drugs for such genetic disease treat symptoms only and must be taken for a patient’s entire lifetime, placing a huge burden on our healthcare system. Scientists have known the cause of many genetic disorders for years, but until now there has been no clear way to reverse them. The IGI aims to use the ‘molecular scalpel’ Cas9 to permanently correct disease-causing mutations in cells, animal models, and eventually human patients. Our member labs are actively developing methods to improve the efficiency, accuracy, precision, and delivery of CRISPR editing molecules. We are deliberately focusing on disorders affecting underserved communities and for which treatment options are currently limited. Our disease targets include cardiovascular conditions, hematopoietic diseases, and ocular disorders. Additionally, we employ high-throughput, genome-wide CRISPR screens to unravel disease pathways and identify targets for therapeutic intervention.